TNIB Investment Highlights HTTP://WWW.SHAKERZAND

[b]TNIB >> Investment Highlights[/b]

HTTP://WWW.SHAKERZANDMOVERZ.COM

Chart forming a bottom with increasing volume

Signs Memorandum of Agreement to Open Pharmaceutical Plant for the Production of IRT-103 (LDN)

Patents filed in China and expected to be filed in USA

Patents and the clinical trials include over 20 years of data



Targeted areas:

Autoimmune states such as rheumatoid arthritis and multiple sclerosis

As an adjunct to antibiotics in the treatment of infectious diseases

In cancer patients undergoing chemotherapy, radiation treatments or surgery

Patients with AIDS, in combination with retroviral drug therapy

In wound healing or herpes viral infections

Symbol is TNIB
News Link: http://finance.yahoo.com/q?s=tnib&ql=1



Please review the videos and articles related to immunotherapy, cancer treatments, and other related topics.




MENK Clinical Trials
MENK Articles
MENK Studies
LDN Clinical Trials
LDN Articles
LDN Studies


Company Overview
TNI BioTech Inc. is a biotech company combating fatal diseases through the activation and mobilization of the body’s immune system using our patented immunotherapy.

Our products and technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS and autoimmune diseases. We have been developing active and adaptive forms of immunotherapies.

Our proprietary technology, therapies and patents, will be used to treat a wide range of cancers. Our most advanced clinical programs involve immunotherapy that works by isolating a patient’s lymphocytes and then incubating them together with Methionine Enkephalin (MENK) in an enriching external incubation system. After incubation the patient’s lymphocytes are reinfused back into the patient where they combat and destroy tumor cells.

TNI BioTech Products


IRT-101 is an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells. This is accomplished by increasing the number of T cells and NK cells, NKT and Gammadelta T cells that destroy infective organisms and tumor cells while simultaneously inhibiting Treg cells.

IRT-102 is an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells and following an enriching external incubation are transfused back into the patient thereby providing the patient with a passive immunity containing large amounts of auto-amplified immune cells that combat cancer cells.

IRT- 103 is an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells. This is accomplished by activating the enkephalin receptor system resulting in increased number of T cells and NK cells that destroy infective organisms and tumor cells.

However, since any condition that results in an altered-immune response is a potential target for investigation. The Company intends to investigate the following valuable candidates:

Autoimmune states such as rheumatoid arthritis and multiple sclerosis.
As an adjuvant to vaccines in the protection from getting infectious diseases
In patients undergoing chemotherapy or radiation treatments in surgery
In wound healing, herpes and shingles in the elderly.
In clinical trials the evidence is significant that LDN/MENK stimulates the immune system and that it is effective in the treatment of some immune-suppressed diseases. The treatment modality has been demonstrated to be effective while avoiding certain deleterious effects on the body, as is often the case with traditional chemotherapy. The costs are reasonable, making this an attractive complement for a large number of cancer patients

Global Investment Media
310-353-6277

Investor Relations
Marlin Molinaro
Marmel Communications, LLC
702-434-8692


Website: http://www.tnibiotech.com/

TNI BioTech, Inc. Signs Memorandum of Agreement to Open Pharmaceutical Plant for the Production of IRT-103 (LDN)Marketwire(Tue 7:48AM EDT)
Dr. Ronald Herberman Joins TNI BioTech Inc. as Senior Vice President of Research and Development and Chief Medical OfficerMarketwire(Thu, Sep 6)
TNI BioTech, Inc. Acquires Portfolio of Exclusive Licenses to the Portfolio of Patents of Dr. Bernard BihariMarketwire(Tue, Aug 28)
TNI BioTech, Inc., in Partnership With GB Oncology and Imaging Group LTD., Signs Agreement With the Republic of MalawiMarketwire(Tue, Aug 7)
TNI BioTech, Inc. Announces Memorandum of Agreement With GB Oncology and Imaging Group LTDMarketwire(Tue, Jul 24)